Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 4/20 | 0.48 |
| ▸ | FABP3 | P05413 | 2/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.32 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.32 |
| ▸ | MDM4 | O15151 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903766 | 0.89 | FABP4 (0.56) | FABP4FABP3FABP5GABRA1GABRB2 | |
| SCHEMBL28217372 | 0.85 | HDAC4 (0.50) | FABP4FABP3FABP5PGRTYR | |
| SCHEMBL14062504 | 0.85 | FABP4 (0.42) | FABP4FABP3FABP5GABRA1GABRB2 | |
| Sulfuric Acid SCHEMBL30910258 | 0.82 | FABP4 (0.60) | FABP4FABP3FABP5GABRA1GABRB2 | |
| SCHEMBL338867 | 0.80 | GABRA1 (0.46) | FABP4FABP3FABP5GABRA1GABRB2 | |
| SCHEMBL11042085 | 0.78 | FABP4 (0.45) | FABP4FABP3FABP5GABRA1GABRB2 | |
| SCHEMBL162818 | 0.78 | FABP4 (0.67) | FABP4FABP3FABP5GABRA1GABRB2 | |
| SCHEMBL21550418 | 0.78 | FABP4 (0.45) | FABP4FABP3FABP5TRPV4ALDH1A1 | |
| SCHEMBL23202783 | 0.77 | GABRA1 (0.43) | FABP4FABP3FABP5GABRA1GABRB2 | |
| Hydrochloric Acid SCHEMBL5790729 | 0.77 | GABRA1 (0.43) | FABP4FABP3FABP5GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109897088-B | Phenylalanine derivative containing N- (2-oxoethyl) benzene sulfonamide and preparation method and application thereof | 山东大学 | 2022-06-17 | — | — | CN | claimed |
| EP-1712601-B1 | Phase change inks | XEROX CORP (US) | 2010-07-28 | — | — | EP | claimed |
| JP-57046941-A | — | — | None | — | — | JP | disclosed |
| EP-4735462-A1 | COMPOUNDS AND USES THEREFOR | GLYCOSYNNOVATIONS PTY LTD (AU) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735463-A1 | COMPOUNDS AND USES THEREFOR | GLYCOSYNNOVATIONS PTY LTD (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2025000059-A1 | COMPOUNDS AND USES THEREFOR | Glycosynnovations Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
| WO-2025000061-A1 | COMPOUNDS AND USES THEREFOR | Glycosynnovations Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
| US-20240238322-A1 | THERAPEUTIC AGENTS AND METHODS OF PRODUCING SAME | Glycosynnovations Pty Ltd (AU) | 2024-07-18 | — | — | US | disclosed |
| US-11903958-B2 | Therapeutic agents and methods of producing same | Glycosynnovations Pty Ltd (AU) | 2024-02-20 | — | — | US | disclosed |
| CN-116731097-A | Amino acid methyl ester substituted uridine and derivatives thereof, preparation method and application thereof | 河南省科学院高新技术研究中心 | 2023-09-12 | — | — | CN | disclosed |
| EP-0396082-A2 | New carnitine derivatives, process for their preparation, and their use in human therapy | FIDIA S.p.A. (IT) | 1990-11-07 | — | — | EP | disclosed |
| EP-0396080-A2 | New serine derivatives, process for their preparation and their use in human therapy | FIDIA S.p.A. (IT) | 1990-11-07 | — | — | EP | disclosed |
| EP-0204264-B1 | CONVERSION OF URACIL DERIVATIVES TO CYTOSINE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 1990-08-16 | — | — | EP | disclosed |
| US-4754026-A | Conversion of uracil derivatives to cytosine derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-06-28 | — | — | US | disclosed |
| EP-0204264-A2 | Conversion of uracil derivatives to cytosine derivatives | Takeda Chemical Industries, Ltd. (JP) | 1986-12-10 | — | — | EP | disclosed |
| US-4480041-A | IMMUNOASSAY | COLLABORATIVE RESEARCH, INC. (US) | 1984-10-30 | — | — | US | disclosed |
| JP-S5746941-A | PREPARATION OF ESTER-TYPE LIQUID MATERIAL | HITACHI LTD | 1982-03-17 | — | — | JP | disclosed |
| US-4078068-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4006204-A | ANTIINFLAMMATORY, PROSTAGLANDIN SYNTHETASE INHIBITORS AND RECEPTOR BLOCKERS | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11903958-B2 | Therapeutic agents and methods of producing same | SIGLEC7, FUT5, UGCG | FABP4 2039/4885FABP3 1653/4885FABP5 1426/4885 |
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | RNMT, RNGTT, NSUN2 | FABP4 3087/4885FABP3 3298/4885FABP5 3024/4885 |
| US-20240238322-A1 | THERAPEUTIC AGENTS AND METHODS OF PRODUCING SAME | SIGLEC7, FUT5, UGCG | FABP4 2039/4885FABP3 1653/4885FABP5 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.